Report predicts world revenues for monoclonal antibody therapies will reach $62.3bn in 2015

Sunday 30 October 2011, Amsterdam

This new report predicts that overall revenues for monoclonal antibody (mAb) therapies will rise between 2011 and 2021. The world mAb drugs market will reach $62.3bn in 2015, up from revenues of $44.6bn (USD) in 2010. Those findings appear in Therapeutic Monoclonal Antibodies: World Market 2011-2021, published in September 2011.

This study forecasts that the monoclonal antibody drug market will expand steadily to 2021. There will be sales growth in established and emerging markets, especially the US, Japan, China and India. The future of mAb technologies is promising, with high demand for novel treatments for cancer, autoimmune diseases and eye disorders in particular.

Diya Lahiri, pharmaceutical industry analyst, said: "The world market for monoclonal antibody treatments will benefit from the entry of new products this decade. There is much scope for therapies that offer improved administration methods, efficacy and tolerability, especially in the autoimmune disorders sector of the market."

This new study predicts how treatments such as Avastin, Herceptin, MabThera, Remicade, Humira, Tysabri and Lucentis will perform to 2021. It shows commercial prospects for Roche, J&J, Abbott, Biogen Idec, Novartis and other companies. Markets and R&D pipelines for mAb-based treatments remain strong.

Products emerging from the R&D pipeline will help the monoclonal antibody treatments industry and market to grow this decade, the report explains. Also, the approval of existing products for new indications will expand the mAbs market and benefit patients.